Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-007 Combined With Toripalimab and Axitinib in Advanced Melanoma
NCT04640545Phase 1Completed
- Sponsor
- Leads Biolabs
- Start
- May 2020
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alcestobart in melanoma, sponsored by Leads Biolabs. Primary endpoints: Number of subjects with adverse events and serious adverse events, Maximum tolerated dose and 1 more. Started May 2020; status: completed.
02
Drugs
alcestobart
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04640545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640545.